A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for 508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation.

  • Kotsimbos, Anastase Thomas (Primary Chief Investigator (PCI))
  • Wilson, John (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date1/03/22 → 31/12/24

Keywords

  • Respiratory medicine
  • Cystic fibrosis
  • Clinical trial

Clinical Trial Phase

  • Phase III (a & b)